Literature DB >> 1719935

Development of a mechanism of action-based screen for anthelmintic microbial metabolites with avermectinlike activity and isolation of milbemycin-producing Streptomyces strains.

C L Haber1, C L Heckaman, G P Li, D P Thompson, H A Whaley, V H Wiley.   

Abstract

A high-volume screen for anthelmintic microbial metabolites with an avermectinlike mode of action was developed. The primary screen used the free-living nematode Caenorhabditis elegans in a whole-organism assay. The specificity for avermectinlike compounds resides in the secondary screen, which takes advantage of the chloride channel-opening properties of the avermectins. By using standard microelectrode techniques, membrane conductance changes following exposure to extracts of microbial cultures were measured in the walking leg stretcher muscle fibers of the lined shore crab Pachygrapsus crassipes. The avermectins and related milbemycins give a characteristic response of rapid loss of membrane resistance coupled with a slight hyperpolarization of the membrane. This is partially (near 50%) reversible with the chloride channel blocker picrotoxinin. Four morphologically similar cultures that produced avermectinlike activities were identified by this screen. Isolation of the active components from one of these cultures (strain UC 8984) followed by nuclear magnetic resonance spectroscopy resulted in the identification of milbemycins alpha 1 and alpha 3. These metabolites are members of a large family of milbemycins produced by Streptomyces hygroscopicus subsp. aureolacrimosus NRRL 5739. Systematic studies revealed that strain UC 8984 is also a S. hygroscopicus strain, but which is taxonomically distinct from NRRL 5739.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719935      PMCID: PMC245273          DOI: 10.1128/AAC.35.9.1811

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  CHEMICAL COMPOSITION OF CELL-WALL PREPARATIONS FROM STRAINS OF VARIOUS FORM-GENERA OF AEROBIC ACTINOMYCETES.

Authors:  B BECKER; M P LECHEVALIER; H A LECHEVALIER
Journal:  Appl Microbiol       Date:  1965-03

2.  System of color wheels for streptomycete taxonomy.

Authors:  H D TRESNER; E J BACKUS
Journal:  Appl Microbiol       Date:  1963-07

3.  A novel series of milbemycin antibiotics from Streptomyces strain E225. I. Discovery, fermentation and anthelmintic activity.

Authors:  J D Hood; R M Banks; M D Brewer; J P Fish; B R Manger; M E Poulton
Journal:  J Antibiot (Tokyo)       Date:  1989-11       Impact factor: 2.649

4.  LL-F28249 antibiotic complex: a new family of antiparasitic macrocyclic lactones. Isolation, characterization and structures of LL-F28249 alpha, beta, gamma, lambda.

Authors:  G T Carter; J A Nietsche; M R Hertz; D R Williams; M M Siegel; G O Morton; J C James; D B Borders
Journal:  J Antibiot (Tokyo)       Date:  1988-04       Impact factor: 2.649

5.  Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance.

Authors:  L C Fritz; C C Wang; A Gorio
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

6.  Ascaris suum: differential effects of avermectin B1a on the intact animal and neuromuscular strip preparations.

Authors:  I S Kass; D A Larsen; C C Wang; A O Stretton
Journal:  Exp Parasitol       Date:  1982-10       Impact factor: 2.011

7.  Milbemycins, a new family of macrolide antibiotics: fermentation, isolation and physico-chemical properties.

Authors:  Y Takiguchi; H Mishima; M Okuda; M Terao; A Aoki; R Fukuda
Journal:  J Antibiot (Tokyo)       Date:  1980-10       Impact factor: 2.649

8.  Milbemycins, a new family of macrolide antibiotics. Studies on the biosynthesis of milbemycins alpha 2, alpha 4 and D using 13C labeled precursors.

Authors:  M Ono; H Mishima; Y Takiguchi; M Terao; H Kobayashi; S Iwasaki; S Okuda
Journal:  J Antibiot (Tokyo)       Date:  1983-08       Impact factor: 2.649

9.  Taxonomy by carbon replication. I. An examination of Streptomyces hygroscopicus.

Authors:  A DIETZ; J MATHEWS
Journal:  Appl Microbiol       Date:  1962-05

10.  A patch-clamp study of effects of dihydroavermectin on Ascaris muscle.

Authors:  R J Martin; A J Pennington
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

View more
  6 in total

1.  Channel-forming properties of the neuropeptide preparation abamectin in bilayer lipid membranes.

Authors:  M G Fomkina; Z Khashaev; V A Drinyaev; L M Chailakhyan
Journal:  Dokl Biochem Biophys       Date:  2001 May-Jun       Impact factor: 0.788

2.  Host as the variable: model hosts approach the immunological asymptote.

Authors:  Arturo Casadevall
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Identification of compounds with bioactivity against the nematode Caenorhabditis elegans by a screen based on the functional genomics of the marine bacterium Pseudoalteromonas tunicata D2.

Authors:  Francesco Ballestriero; Torsten Thomas; Catherine Burke; Suhelen Egan; Staffan Kjelleberg
Journal:  Appl Environ Microbiol       Date:  2010-07-02       Impact factor: 4.792

4.  Nodulisporic acid produces direct activation and positive allosteric modulation of AVR-14B, a glutamate-gated chloride channel from adult Brugia malayi.

Authors:  Shivani Choudhary; Melanie Abongwa; Sudhanva S Kashyap; Saurabh Verma; Gunnar R Mair; Daniel Kulke; Richard J Martin; Alan P Robertson
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

Review 5.  Combating Parasitic Nematode Infections, Newly Discovered Antinematode Compounds from Marine Epiphytic Bacteria.

Authors:  Nor Hawani Salikin; Jadranka Nappi; Marwan E Majzoub; Suhelen Egan
Journal:  Microorganisms       Date:  2020-12-11

6.  Synthesis and Immunological Evaluation of Virus-Like Particle-Milbemycin A₃/A₄ Conjugates.

Authors:  Andris Zeltins; Māris Turks; Dace Skrastina; Jevgeņija Lugiņina; Ieva Kalnciema; Ina Balke; Ērika Bizdēna; Vitalijs Skrivelis
Journal:  Antibiotics (Basel)       Date:  2017-09-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.